^
Association details:
Evidence:
Evidence Level:
Resistant: B - Late Trials
Title:

The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Trial

Published date:
05/18/2021
Excerpt:
...newly diagnosed acute myeloid leukemia (AML) from our FLUGAZA phase III clinical trial (PETHEMA group)...In the treatment-adjusted multivariate survival analyses, only the NRAS (hazard ratio (HR), 1.9, p = 0.005) and TP53 (HR, 2.6, p = 9.8 × 10-7) variants were associated with shorter overall survival (OS)...
DOI:
10.3390/cancers13102458
Trial ID:
Evidence Level:
Resistant: C3 – Early Trials
Title:

The Prognostic Ability of RAS Pathway-Related Gene Mutations in Patients with Myeloid Neoplasms Treated with Hypomethylating Agents

Published date:
07/07/2021
Excerpt:
...treated with decitabine or azacitidine as a frontline therapy...diagnosis of AML (hazard ratio 2.915), and mutations in NRAS (hazard ratio 4.440) were identified as poor prognostic factors for survival....Particularly, mutated NRAS was associated with inferior survival rates.
DOI:
10.1159/000516793